ROI

With 46% of developers distrusting AI code, Qodo 2.0's new multi-agent architecture aims to restore faith by delivering more accurate, context-aware reviews.

Ripple Prime's new integration with top derivatives protocol Hyperliquid provides a capital-efficient, risk-managed gateway for institutional finance into DeFi.

A new partnership is trading vague online metrics for real-world visits, proving advertising's impact and reshaping how tourist destinations spend money.

The frozen potato giant appoints an AB InBev veteran as Executive Chair and a new CFO, signaling a major push for global expansion and shareholder value.

The AI boom runs on powerful chips that generate immense heat. Discover how the once-overlooked HVAC industry is now a critical infrastructure investment.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

Fold's new app aims to make bitcoin simple for daily use, but can it stand out in a crowded market and deliver on its long-term promises?

With a new AWS competency and proprietary AI tools, this firm is helping small businesses tackle big tech challenges like legacy system modernization.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

Caribou Biosciences unveils new data showing its 'off-the-shelf' CAR-T cells achieve deep, lasting responses in lymphoma and myeloma clinical trials.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Nasdaq-listed Zeta Network Group is exploring real-world asset tokenization, signaling a pivotal move beyond Bitcoin for institutional treasury management.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

With a 90% clinical trial failure rate, BullFrog AI is launching a new tool to help drugmakers make smarter, risk-balanced R&D decisions.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

With $125M in new funding from steel and cement makers, newcleo accelerates its plan to turn nuclear waste into clean energy for heavy industry.

VENU closes a $13M deal for its first indoor venue, bringing an innovative fractional ownership "FireSuite" concept to the Denver area.

A landmark survey reveals a massive capital rotation as 96% of institutions chase AI and 81% move to private markets to navigate a fragmenting world.